Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $32 and keeps a Sell rating on the shares. The firm updated the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback